Using real-world data to evaluate biosimilar switching

被引：0
|
作者：
Dutcher, Sarah K. [1 ]
Eworuke, Efe [1 ]
Blum, Michael D. [1 ]
Ball, Robert [1 ]
机构：
[1] US FDA, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷 / 07期
关键词：
INFLIXIMAB;
D O I：
10.1002/pds.4899
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：814 / 816
页数：3
相关论文
共 50 条
  • [1] Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
    Ashish Sharma
    M. Hafeez Faridi
    Nilesh Kumar
    Nikulaa Parachuri
    Rohini Sharma
    Baruch D. Kuppermann
    Francesco Bandello
    Anat Loewenstein
    Carl D. Regillo
    Eye, 2020, 34 : 1008 - 1009
  • [2] Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
    Sharma, Ashish
    Hafeez Faridi, M.
    Kumar, Nilesh
    Parachuri, Nikulaa
    Sharma, Rohini
    Kuppermann, Baruch D.
    Bandello, Francesco
    Loewenstein, Anat
    Regillo, Carl D.
    EYE, 2020, 34 (06) : 1008 - 1009
  • [3] SWITCHING TO BIOSIMILAR INFLIXIMAB: REAL-WORLD DATA FROM THE SOUTHAMPTON BIOLOGIC THERAPIES REVIEW SERVICE
    Holroyd, Christopher
    Parker, Lucy
    Bennett, Sarah
    Zarroug, Jalaa
    Underhill, Caron
    Davidson, Brian
    Armstrong, Ray
    Harvey, Nick
    Dennison, Elaine
    Cooper, Cyrus
    Edwards, Christopher J.
    RHEUMATOLOGY, 2016, 55 : 60 - 61
  • [4] Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar
    Kay, Jonathan
    Doerner, Thomas
    Emery, Paul
    Kvien, Tore K.
    Breedveld, Ferdinand C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (04) : E44 - +
  • [5] A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATION
    Denysyk, L.
    Doyle, J.
    Sood, R.
    VALUE IN HEALTH, 2018, 21 : S89 - S89
  • [6] Efficacy and safety of filgrastim biosimilar Accofil® - real-world data
    Denzlinger, C.
    Taenzer, M.
    Kahner-Groene, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 239 - 239
  • [7] OUTCOMES OF BIOSIMILAR ADALIMUMAB SWITCHBACKS/REVERSE SWITCHING IN IBD: REAL-WORLD EXPERIENCE
    Norredinvand, Hesam Ahmadi
    Bishop, Sophia
    Patel, Janki
    Sivanesan, Naveenaa
    Fong, Steven
    GUT, 2021, 70 : A94 - A94
  • [8] REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
    Melville, A.
    Yusof, M. Y. Md
    Fitton, J.
    Bailey, L.
    Emery, P.
    Buch, M. H.
    Dass, S.
    Saleem, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 299 - 300
  • [9] SWITCHING TO BIOSIMILAR ADALIMUMAB: A REAL WORLD STUDY
    Begum, Julie
    Nisar, Muhammad K.
    RHEUMATOLOGY, 2020, 59
  • [10] SWITCHING TO BIOSIMILAR RITUXIMAB: A REAL WORLD STUDY
    Nisar, Muhammad K.
    RHEUMATOLOGY, 2019, 58
12345